Zimmer Biomet Holdings (ZBH) said Friday that the US Food and Drug Administration has granted 510(k) clearance for its OsseoFit Stemless Shoulder System, a new total shoulder replacement implant.
The company said the system is designed to match the natural humeral anatomy to optimize anatomical fit while preserving healthy bone.
The OsseoFit Stemless Shoulder System is expected to be commercially available in the first quarter of 2025, it added.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.